Core Insights - Danaher Corporation reported a strong finish for 2025 with sales of $24.6 billion and a 2% core revenue growth, alongside an adjusted diluted EPS of $7.80, reflecting a 4.5% increase [3][4][7] - The company anticipates core revenue growth of 3% to 6% for 2026, with adjusted EPS guidance set between $8.35 and $8.50 [5][15] Financial Performance - For the fourth quarter, Danaher achieved sales of $6.8 billion and a 2.5% core revenue growth, with developed markets showing low single-digit growth and high-growth markets up mid-single digits [8] - Adjusted gross margin was reported at 58.2% and adjusted operating margin at 28.3%, both down 130 basis points year-over-year [9] Segment Performance - The biotechnology segment saw a core revenue increase of 6%, driven by high single-digit growth in bioprocessing [9][10] - Life sciences segment core revenue increased by 0.5%, with a modest recovery in pharma, particularly in Europe, while academic and government demand remained muted [12] - The diagnostics segment reported a 2% core revenue increase, with clinical diagnostics growing mid-single digits [13] Product Innovation - Investment in innovation led to approximately 25% year-over-year growth in new product revenue, with significant launches in bioprocessing, life sciences, and diagnostics [6][19] - The introduction of the ZenoTOF 8600 mass spectrometry system by SCIEX is noted for delivering up to 30 times increased sensitivity compared to previous platforms [2] Future Outlook - Danaher expects high single-digit growth in bioprocessing for 2026, supported by consumables, while equipment revenue is projected to improve to approximately flat for the year [16] - The company anticipates approximately $1.8 billion in respiratory revenue for 2026, assuming a typical season and stable customer testing protocols [14]